Table 5 Relative expression of mRNA levels in tumor samples after ex vivo exposure to doxorubicin. The IC50 concentrations for the samples tested are shown for each drug (median and range). The p values have been calculated using non-parametric statistics, in detail the Wilcoxon matched pairs test. On statistical advice, we chose not to use a Bonferroni's correction, but it should be noted that some technically statistically significant results could have arisen by chance.
| Â | Breast samples | Ovarian samples | ||||||
|---|---|---|---|---|---|---|---|---|
Target gene | n | Control | Doxorubicin IC50 = 0.828 μM (0.569–1.16) | p | n | Control | Doxorubicin IC50 = 1.34 μM (0.310–17.7) | p |
BCRP | 14 | 0.039 | 0.044 | 0.8077 | 12 | 0.010 | 0.027 | 0.042 |
ERCC1 | 14 | 0.711 | 0.826 | 0.2412 | 11 | 0.440 | 0.506 | 0.4922 |
MDR1 | 14 | 0.069 | 0.056 | 0.0494 | 12 | 0.005 | 0.005 | 0.2036 |
MRP1 | 14 | 3.886 | 5.692 | <0.0001 | 12 | 1.890 | 2.321 | 0.083 |
MVP | 14 | 4.990 | 6.925 | 0.0023 | 12 | 2.251 | 2.687 | 0.042 |
TOPO I | 14 | 5.464 | 5.128 | 0.0419 | 12 | 6.112 | 3.360 | 0.001 |
TOPO IIα | 14 | 0.546 | 0.017 | <0.0001 | 12 | 1.491 | 0.089 | 0.0015 |
TOPO IIβ | 14 | 6.617 | 6.461 | 0.0785 | 12 | 5.907 | 5.252 | 0.0322 |